News | January 03, 2024
Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Furthering cell therapy ambition across oncology and autoimmune diseases
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated
